Exanthema Epidemiology Forecast 2025-2034

Exanthema refers to widespread skin rashes often caused by viral infections like measles and chickenpox. In 2023, the World Health Organization estimated that 10.3 million measles cases infected people, highlighting its burden. Since the United States introduced the chickenpox vaccine in 1995, infections declined by 97%, preventing 91 million cases over 25 years.

Exanthema Epidemiology Forecast Report Coverage

The “Exanthema Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of exanthema. It projects the future incidence and prevalence rates of exanthema across various populations. The study covers age and type as major determinants of the exanthema-affected population. The report highlights patterns in the prevalence of exanthema over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of exanthema in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Exanthema: Disease Overview

Exanthema refers to a rash or skin eruption, often a sign of an underlying systemic infection. It is characterised by red, blotchy, or raised spots that can appear on the face, torso, or limbs. Exanthema is typically associated with viral infections such as measles, rubella, or chickenpox, but can also be caused by bacterial infections, drug reactions, or autoimmune conditions. The rash may be accompanied by other symptoms like fever, malaise, and fatigue. Diagnosis is based on the rash's appearance, associated symptoms, and clinical history, guiding appropriate treatment.

Exanthema: Treatment Overview

For viral infections like measles or rubella, supportive care is recommended, including hydration, pain relief, and fever management. Antibiotics are prescribed for bacterial infections, while antihistamines or corticosteroids may be used for allergic reactions. If the rash is drug-induced, stopping the offending medication is essential. In severe cases, systemic treatments such as immunosuppressive therapy might be required. Prompt diagnosis and targeted treatment are key to managing exanthema effectively.

Epidemiology

The exanthema epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for exanthema by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for exanthema and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Exanthema is commonly linked to viral infections such as Mpox, measles, and chickenpox, which present as widespread skin rashes.
• In 2023, the World Health Organization estimated 10.3 million measles cases, highlighting the significant burden of exanthema-related viral infections.
• Since the introduction of the U.S. chickenpox vaccine in 1995 as part of routine childhood immunisation, infections have declined by 97%, reducing exanthema cases.
• Over 25 years, the U.S. Chickenpox Vaccination Program prevented an estimated 91 million chickenpox cases, saving USD 23.4 billion in healthcare costs, and demonstrating vaccination’s impact on exanthema prevention.

Country-wise Exanthema Epidemiology

The exanthema epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

Exanthema remains a global concern, with 10.3 million measles cases reported in 2023 which is a 20% increase from 2022, according to the World Health Organization and the U.S. Centers for Disease Control and Prevention (CDC). Measles, a major cause of exanthema, highlights the importance of vaccination in disease prevention. Recognizing the impact of such diseases, the JCVI announced in November that two doses of varicella vaccination are now recommended for all infants at 12 and 18 months.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of exanthema based on several factors.
• Exanthema Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of exanthema are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of exanthema epidemiology in the 8 major markets?
• What will be the total number of patients with exanthema across the 8 major markets during the forecast period?
• What was the country-wise prevalence of exanthema in the 8 major markets in the historical period?
• Which country will have the highest number of exanthema patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of exanthema during the forecast period of 2025-2034?
• What are the currently available treatments for exanthema?
• What are the disease risks, signs, symptoms, and unmet needs of exanthema?

This product will be delivered within 3-5 business days.